RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Medulloblastoma: studio delle vie molecolari di sviluppo e progressione tumorale allo scopo di identificare approcci terapeutici innovativi
• 2 - Studio delle basi molecolari e cellulari della risposta alla terapia mirata con inibitori delle tirosin-kinasi per l'ottimizzazione del trattamento delle leucemia Philadelphia positive
• 3 - Progettazione, sintesi e valutazione biologica di inibitori enzimatici e di induttori dell'apoptosi utili come agenti antitumorali
• 4 - La cardiotossicità da terapia anti-neoplastica coinvolge le cellule staminali e progenitori miocardici residenti
• 5 - Ruolo fisiopatologico di poli(ADPR)polimerasi (PARP) e sue implicazioni terapeutiche.
• 6 - Isolamento e caratterizzazione molecolare e funzionale delle cellule staminali leucemiche (LSCs) per lo sviluppo di nuove strategie terapeutiche.
• 7 - Carcinoma papillare della tiroide sdifferenziato: caratteristiche cliniche, cellulari, molecolari; sintesi e farmacologia preclinica di nuovi agenti terapeutici inibitori delle tirosinchinasi.
• 8 - Progettazione, sintesi e attività biologica di inibitori di metalloenzimi coinvolti nelle patologie neurodegenerative, infiammatorie e tumorali.
• 9 - BERSAGLI MOLECOLARI PER NUOVE TERAPIE ANTINEOPLASTICHE ATTRAVERSO LO STUDIO DI PROTEINE-SEGNALE CELLULARI E VIRALI E DI INIBITORI SPECIFICI
• 10 - Sviluppo di derivati chinolonici ed di altri eterocicli azotati come agenti anti-HIV: progettazione, sintesi, studio delle interazioni con nuovi target (IN, RNasi H, Tat/TAR) e modulazione della farmaco-resistenza (NNRTI)

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • PATOLOGIA GENERALE
  • MALATTIE DEL SANGUE
• Area scientifico disciplinare: Scienze chimiche
  • CHIMICA FARMACEUTICA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)

Classificazione geografica

• Regione: Toscana

Bibliografia

Minucci S and Pelicci GP (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6,38-51 Review

Garcia-Manero G et al. (2005) Histone Deacetylase Inhibitors: A Review of Their Clinical Status as Antineoplastic Agents Cancer Invest 23, 635–642

Dokmanovic M and PA Marks (2005) Prospects: Histone Deacetylase Inhibitors. J Cel Biochem 96, 293–304

Suzuki T and Miyata N (2005) Non-hydroxamate histone deacetylase inhibitors. Curr Med Chem 12, 2867-80

Bertos NR et al. (2001) Class II histone deacetylases: structure, function, and regulation. Biochem Cell Biol 79, 243-52 Review

Mai Aet al. (2005) Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 25, 261-309 Review

Warrell RP Jr et al. (1991) Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324, 1385-139

Pandolfi PP (2001) Transcription therapy for cancer. Oncogene 20, 3116-3127

Huang M et al. (1988) Use of all trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72, 567-572

Melnick A and Licht JD (1999) Deconstructing a disease: RARa, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93, 3167-3215

Monneret C (2005) Histone deacetylase inhibitors. Eur J Med Chem 40, 1-13

Miller WH Jr et al. (2002) Mechanism of action of arsenic trioxide. Cancer Res 62, 3893-3903

Lowenberg B et al. (2003) Acute myeloid leukemia and acute promyelocytic leukemia. Hematology (Am Soc Hematol Educ Prog) 82-101

Wang Z (2003) Ham-Wasserman lecture: treatment of acute leukemia by inducing differentiation and apoptosis. Hematology (Am Soc Hematol Educ Prog) 1-13

Miller WJ and Waxman S (2002) Differentiation induction as a treatment for hematologic malignancies. Oncogene 21, 3496-3506

Yang L et al. (2003) Gene expression profiling during all-trans retinoic acid-induced cell differentiation of acute promyelocytic leukemia cells. J Mol Diagn 5, 212-21

Tenen DG (2003) Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 3(2), 89-101

Kantarjian H et al. (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346, 645652

Warrel RP Jr, et al. (1998) Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylases. J Natl Cancer Inst 90, 1621-1625

Richon VM et al. (1996) Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. PNAS 93, 5705-5708

Richon VM et al. (1998) A class of hybrid polar inducers of trasfromed cell differentiation inhibits histone deacetylases. PNAS 95, 3003-3007

Gottlicher M et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20, 6969-6978

Minucci S et al. (2001) Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20, 3110-5

Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nature 403, 41-5

Bennett JM, et al. (1976) Proposals for the classification of the acute leukaemias. french- american-british (FAB) co-operative group. Br J Haematol 33 451-458

Drexler HG (1987) Classification of acute myeloid leukemias--a comparison of FAB and immunophenotyping. Leukemia 1, 697-705

Mecucci C et al. (2002) Genetic profile of acute myeloid leukemia. Rev Clin Exp Hematol 6, 3-25

Ferrari S et al. (1992) Proliferation, differentiation arrest, and survival in leukemic blast cells. Ann NYAcad Sci 663, 202-214

James SY et al. (1999) Leukemia cell differentiation: cellular and molecular interactions of retinoids and vitamin D. Gen Pharmacol 32, 143-154

Huang S, Ingber DE (1999) The structural and mechanical complexity of cell-growth control. Nat Cell Biol 1, 131-138

Insinga A, Silvia Monestiroli, Ronzoni S, et al. (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nature Medicine 11, 71-76

Nebbioso A, et al. (2005) Tumor-selective action of HDAC inhibitors involves TRAIL- induction in acute myeloid leukemia cells. Nature Medicine 11, 77-84

Brown R, Strathdee G (2002) Epigenomics and epigenetic therapy of cancer. Trends Mol Med S43-8

Singal R and Ginder GD (1999) DNA methylation, Blood 93, 4059-4070

Ekmekci CG et al (2004) Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia. Am J Hematol 77, 233-40

Di Croce L et al (2004) Altered epigenetic signals in human disease. Cancer Biol Ther 3, 831-7

Snyder F (1990) Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediator. Am J Physiol 259, C697-708

Heuer HO (1990) Pharmacology of hetrazepines as PAF-antagonists. (Braquet P, ed) Chap 8, pp. 171-202, CRC press, Boca Raton, Florida

Cellai C et al. (2002) Specific PAF antagonist WEB-2086 induces terminal differentiation of murine and human leukemia cells. FASEB J 16, 733-735

Laurenzana A et al. (2005) WEB-2086 and WEB-2170 trigger apoptosis in both ATRA-sensitive and -resistant promyelocytic leukemia cells and greatly enhance ATRA differentiation potential. Leukemia 19, 390-395

Adamus WS et al.(1989) Safety, tolerability, and pharmacologic activity of multiple doses of new platelet activating factor antagonist WEB 2086 in human subjects. Clin Pharmacol Ther 45, 270-276

Parole Chiave

INIBITORI DELLE DEACETILASI ISTONICHE, LEUCEMIE MIELOIDI ACUTE, DIFFERENZIAMENTO CELLULARE, APOPTOSI, TERAPIA DIFFERENZIATIVA, ESPRESSIONE GENICA, DNA MICROARRAY